# | Title | Journal | Year | Citations |
---|
1 | Doxorubicin pathways | Pharmacogenetics and Genomics | 2011 | 1,167 |
2 | Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily | Pharmacogenetics and Genomics | 2005 | 708 |
3 | Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions | Pharmacogenetics and Genomics | 2006 | 583 |
4 | A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs | Pharmacogenetics and Genomics | 2008 | 528 |
5 | SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid | Pharmacogenetics and Genomics | 2006 | 425 |
6 | Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability | Pharmacogenetics and Genomics | 2005 | 419 |
7 | Very important pharmacogene summary | Pharmacogenetics and Genomics | 2011 | 366 |
8 | Metformin pathways | Pharmacogenetics and Genomics | 2012 | 366 |
9 | Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients | Pharmacogenetics and Genomics | 2005 | 355 |
10 | Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells | Pharmacogenetics and Genomics | 2005 | 339 |
11 | Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population | Pharmacogenetics and Genomics | 2009 | 335 |
12 | CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure | Pharmacogenetics and Genomics | 2007 | 332 |
13 | Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans | Pharmacogenetics and Genomics | 2006 | 326 |
14 | Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury | Pharmacogenetics and Genomics | 2007 | 301 |
15 | Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues | Pharmacogenetics and Genomics | 2007 | 300 |
16 | Valproic acid pathway | Pharmacogenetics and Genomics | 2013 | 270 |
17 | Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28 | Pharmacogenetics and Genomics | 2007 | 259 |
18 | PharmGKB summary | Pharmacogenetics and Genomics | 2015 | 243 |
19 | OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine | Pharmacogenetics and Genomics | 2008 | 241 |
20 | Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis | Pharmacogenetics and Genomics | 2005 | 237 |
21 | Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz | Pharmacogenetics and Genomics | 2005 | 232 |
22 | The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c | Pharmacogenetics and Genomics | 2011 | 216 |
23 | The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability | Pharmacogenetics and Genomics | 2005 | 209 |
24 | Cytochrome P450 2C9-CYP2C9 | Pharmacogenetics and Genomics | 2010 | 205 |
25 | Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients | Pharmacogenetics and Genomics | 2007 | 204 |
26 | Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin | Pharmacogenetics and Genomics | 2009 | 202 |
27 | Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans | Pharmacogenetics and Genomics | 2011 | 188 |
28 | Clopidogrel pathway | Pharmacogenetics and Genomics | 2010 | 184 |
29 | PharmGKB summary | Pharmacogenetics and Genomics | 2013 | 184 |
30 | Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin | Pharmacogenetics and Genomics | 2010 | 175 |
31 | Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants | Pharmacogenetics and Genomics | 2007 | 172 |
32 | Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting | Pharmacogenetics and Genomics | 2013 | 170 |
33 | Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response | Pharmacogenetics and Genomics | 2009 | 168 |
34 | HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients | Pharmacogenetics and Genomics | 2009 | 167 |
35 | Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability | Pharmacogenetics and Genomics | 2005 | 166 |
36 | Generation of gene knockouts and mutant models in the laboratory rat by ENU-driven target-selected mutagenesis | Pharmacogenetics and Genomics | 2006 | 161 |
37 | ??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapy | Pharmacogenetics and Genomics | 2005 | 160 |
38 | Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales | Pharmacogenetics and Genomics | 2009 | 160 |
39 | HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms | Pharmacogenetics and Genomics | 2010 | 160 |
40 | Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation | Pharmacogenetics and Genomics | 2005 | 159 |
41 | Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population | Pharmacogenetics and Genomics | 2005 | 155 |
42 | The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans | Pharmacogenetics and Genomics | 2011 | 153 |
43 | PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity | Pharmacogenetics and Genomics | 2006 | 151 |
44 | Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz | Pharmacogenetics and Genomics | 2006 | 145 |
45 | Genome-wide association studies in pharmacogenomics | Pharmacogenetics and Genomics | 2013 | 144 |
46 | Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer's and Parkinson's diseases | Pharmacogenetics and Genomics | 2005 | 143 |
47 | Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data | Pharmacogenetics and Genomics | 1999 | 142 |
48 | PharmGKB summary | Pharmacogenetics and Genomics | 2012 | 141 |
49 | The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects | Pharmacogenetics and Genomics | 2005 | 139 |
50 | Celecoxib pathways | Pharmacogenetics and Genomics | 2012 | 138 |